PulseSight Therapeutics has dosed the first subject in the Phase I trial of its first-in-class non-viral vectorised therapy, PST-611, targeting dry age-related macular degeneration (AMD) and geographic atrophy (GA).
The first-in-human single ascending dose study trial, known as PST-611-CT1, is designed to evaluate the tolerability and safety of the therapy.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
It will involve between six and 12 patients diagnosed with dry AMD/GA. The goal is to determine the safety profile of PST-611 and identify the maximum tolerated dose in preparation for the subsequent Phase IIa trial.
The company expects to release preliminary findings by early 2026, contingent on the rate of patient enrolment.
The clinical study is taking place in Paris and Grenoble, France, under the guidance of Professor Francine Behar-Cohen, from Cochin – Assistance Publique-Hôpitaux de Paris (AP-HP), who is also credited as the inventor of the technology.
Professor Christophe Chiquet from CHU Grenoble Alpes’ ophthalmology department is also involved in the trial.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataDysregulation of iron homeostasis is found in dry AMD, resulting in free iron accumulation that can lead to oxidative stress, inflammation, and cell death within the retina.
PulseSight Therapeutics CEO Judith Greciet said: “Supported by the previous clinical demonstration of the safety profile of our innovative delivery technology and a solid pre-clinical package, we believe PST-611 holds the potential to improve both anatomical and functional features of dry AMD/GA.
“Moreover, the sustained and long-lasting expression of transferrin should help reduce the need for frequent reinjections, strongly improving patients’ compliance with the treatment. Once the safety and the maximal dose are confirmed, our goal is to swiftly move into a phase IIa proof-of-concept study, to demonstrate the ability of transferrin to protect retinal cells from atrophy and preserve vision.”
